Sparks commentary - Chosa

Healthcare

Sparks - Chosa

More on this equity
CHOSA Oncology targets first US Platin-DRP revenues in summer 2027
Published by Arron Aatkar, PhD

CHOSA Oncology has secured an agreement with a CLIA certified laboratory to develop and validate Platin-DRP, its test designed to identify lung cancer patients most likely to benefit from platinum chemotherapy. The company targets first US revenues in summer 2027, subject to successful validation, with management forecasting 300 to 500 tests sold in the first year.

The agreement builds on results from an 82 patient analysis of the Phase III SPLENDOUR trial, where higher Platin-DRP scores were associated with median overall survival of 16.9 months versus 5.5 months for lower scores. Further clinical evidence is expected in Q127 from CHOSA’s collaboration with Mount Sinai, which is assessing the test in patients receiving platinum chemotherapy alongside immunotherapy.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.